A novel new test for bacteria in fluids makes it as easy as observing a color change to confirm the presence of disease-causing pathogens, promising much easier diagnostic tests and greater food safety.
Marinus parts ways with 20% of its workforce – Pharmaceutical Technology
Oral ganaxolone, marketed under the brand name Ztalmy, first received FDA approval to treat seizures associated with CDKL5 deficiency disorder in March 2022. Credits: Tunatura/Shutterstock.com
May 9, 2024